Global Viscosupplementation Market Size By Type (Hip Osteoarthritis, Shoulder Osteoarthritis), By Application (Hospitals, ASCs), By Region, And Segment Forecasts, 2023 to 2032

lobal Viscosupplementation Market Report Description

The Global Viscosupplementation Market was valued at USD 3.1 billion in 2023 and is projected to reach USD 6.4 billion by 2031, growing at a CAGR of 9.4% during the forecast period. This market is witnessing significant growth due to the increasing prevalence of osteoarthritis, a rise in the aging population, and growing preference for minimally invasive treatments. Viscosupplementation, which involves the injection of hyaluronic acid into the joints, particularly the knee, provides an effective alternative for managing joint pain and delaying joint replacement surgeries.

Drivers:

Increasing Prevalence of Osteoarthritis:

Osteoarthritis affects millions globally, and its incidence is on the rise due to aging demographics and lifestyle factors such as obesity and sedentary habits. Viscosupplementation provides a non-surgical solution for managing pain and improving mobility.

Growing Geriatric Population:

With an increasing elderly population, the demand for joint health solutions is escalating. Older individuals are more likely to suffer from degenerative joint disorders, making them prime candidates for viscosupplementation.

Preference for Minimally Invasive Procedures:

Patients and physicians alike are shifting toward treatments that offer faster recovery times, fewer complications, and lower overall healthcare costs. Viscosupplementation fits these criteria, bolstering its market demand.

Restraints:

Limited Long-Term Efficacy:

Although viscosupplementation offers short-term relief, questions remain about its long-term effectiveness compared to other treatment options. This skepticism can impact its adoption rate among healthcare providers.

Reimbursement Challenges:

In some regions, limited or inconsistent insurance coverage for viscosupplementation procedures poses a barrier to widespread use, especially in cost-sensitive healthcare environments.

Opportunity:

R&D in Novel Formulations:

Ongoing research in extended-release and next-generation hyaluronic acid products is expected to enhance the efficacy and duration of relief, opening new avenues for market players.

Expansion in Emerging Economies:

Rapid healthcare infrastructure development and increasing awareness of joint health in regions such as Asia-Pacific and Latin America present untapped market potential.

Market by System Type Insights:

The Single Injection Viscosupplementation segment accounted for the largest market share in 2023. This is attributed to its convenience, better patient compliance, and reduced need for multiple clinical visits. However, the Three-Injection System segment continues to be utilized for patients requiring prolonged relief, particularly in more advanced osteoarthritis cases.

Market by End-use Insights:

Hospitals emerged as the leading end-use segment in 2023, driven by the availability of skilled professionals and infrastructure for administering intra-articular injections. Orthopedic Clinics are also gaining traction due to the rise in outpatient visits and personalized care models.

Market by Regional Insights:

North America dominated the global viscosupplementation market in 2023, fueled by high osteoarthritis prevalence, advanced healthcare systems, and strong reimbursement policies. Asia-Pacific is projected to exhibit the fastest growth rate during the forecast period, supported by a large aging population, rising healthcare awareness, and improving access to joint care treatments.

Competitive Scenario:

Key players in the global viscosupplementation market include Sanofi S.A., Zimmer Biomet, Anika Therapeutics Inc., Ferring Pharmaceuticals, Bioventus LLC, Seikagaku Corporation, Chugai Pharmaceuticals, Fidia Farmaceutici S.p.A., Lifecore Biomedical, and LG Chem. These companies are actively pursuing strategies such as product innovation, regulatory approvals, and geographic expansion.

Scope of Work – Global Viscosupplementation Market

Report Metric Details

Market Size (2023) USD 3.1 billion

Projected Market Size (2031) USD 6.4 billion

CAGR (2023–2031) 9.4%

Market Segments System Type (Single Injection, Three-Injection), End-use (Hospitals, Clinics)

Growth Drivers Aging population, increasing osteoarthritis cases, preference for non-surgical treatment

Opportunities Product innovation, market expansion in Asia-Pacific and Latin America

Key Market Developments:

2023: Sanofi S.A. launched an enhanced formulation of its single-injection viscosupplement, offering extended pain relief for knee osteoarthritis.

2024: Bioventus LLC acquired a hyaluronic acid product line from a regional player to expand its offerings in Asia.

2025: Zimmer Biomet received FDA approval for a new delivery system aimed at improving patient comfort and injection accuracy.

FAQs:

1. What is the current market size of the Global Viscosupplementation Market?

The market size was USD 3.1 billion in 2023.

2. What is the major growth driver of the Global Viscosupplementation Market?

The increasing prevalence of osteoarthritis and the demand for minimally invasive treatments are key growth drivers.

3. Which is the largest region during the forecast period in the Global Viscosupplementation Market?

North America is projected to remain the largest region throughout the forecast period.

4. Which segment accounted for the largest market share in the Global Viscosupplementation Market?

The Single Injection segment accounted for the largest market share in 2023.

5. Who are the key market players in the Global Viscosupplementation Market?

Key players include Sanofi S.A., Zimmer Biomet, Anika Therapeutics, Bioventus LLC, and Ferring Pharmaceuticals.

Let me know if you’d like this converted into a downloadable document or adapted for presentation.